Quarterly ResultMay 14, 2026, 04:14 PM
Revium Rx Q1 Net Loss $725K; Going Concern Doubt Raised
AI Summary
Revium Rx reported a net loss of $725,000 for Q1 2026, an increase of 14.3% from $634,000 in Q1 2025. The company faces substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $25.7 million and a need for further investment. While the Nano-Mupirocin program advanced to Phase 1 clinical trials, other key programs like Nano-Candesartan and LPLT experienced delays.
Key Highlights
- Reported Q1 2026 net loss of $725,000, up 14.3% from $634,000 in Q1 2025.
- Accumulated deficit reached $25.7 million as of March 31, 2026.
- Cash and cash equivalents, plus short-term deposits, totaled $2.1 million.
- Research and development expenses increased 116.9% to $473,000 in Q1 2026.
- General and administrative expenses decreased 48.7% to $266,000 in Q1 2026.
- Received Israeli Ministry of Health approval to initiate Phase 1 clinical trials for Nano-Mupirocin.
- Nano-Candesartan and LPLT/Vaccine programs experienced delays.
- Management raised substantial doubt about the company's ability to continue as a going concern.